New Website for People Impacted by Age-Related Macular Degeneration Launched by Patient Advocacy Groups prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
LAS VEGAS, March 17, 2021 /PRNewswire/ DelveInsight s
Wet Age-Related Macular Degeneration (Wet AMD) Market report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the Wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the
The introduction of Anti-vascular endothelial growth factor (VEGF) as a standard Wet AMD treatment has led to a significant improvement in patients prognosis, allowing recovery and maintenance of visual function in the vast majority of cases.
Oxurion NV Business and Financial Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position.
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position.